Who this is for
Men and other people with a prostate who have no symptoms. All three bodies below flag the same higher-risk groups: Black men, and men with a father or brother diagnosed young. AUA adds germline mutations such as BRCA. USPSTF names the same risk factors but sets no separate start age for them; ACS and AUA both do.
None of this applies if you already have symptoms, such as difficulty urinating or blood in the urine or semen. That is evaluation, not screening, and it should not wait for a screening schedule.
Every body here also puts life expectancy above age. ACS is explicit: men with less than a 10-year life expectancy should not be offered screening, and overall health status, not age alone, drives the decision.
Where the recommendations diverge
- USPSTF 55 to 69
- ACS 50 and older
- ACS 45 and older
- AUA 40 and older
- AUA 45 and older
- AUA 50 to 69
For men aged 55 to 69 years, the decision to undergo periodic prostate-specific antigen (PSA)-based screening for prostate cancer should be an individual one. Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision.
Our note: USPSTF lists this topic as under update; the 2018 statement is still current. It grades D against PSA screening at 70 and older, and adds that clinicians should not screen men who do not express a preference for screening.
The American Cancer Society recommends that men have a chance to make an informed decision with their health care provider about whether to be screened for prostate cancer ... The discussion about screening should take place at: Age 50 for men who are at average risk of prostate cancer and are expected to live at least 10 more years
Our note: The ellipsis omits one sentence: "The decision should be made after getting information about the possible benefits, risks, and uncertainties of prostate cancer screening." The Age 50 line is a list item with no terminal period in the source. At 50 ACS recommends the conversation, not the test.
The discussion about screening should take place at: ... Age 45 for men at high risk of developing prostate cancer. This includes African American men and men who have a first-degree relative (father or brother) diagnosed with prostate cancer at an early age (younger than age 65).
Our note: The ellipsis omits the Age 50 average-risk bullet, which is the row above. What happens at 45 is the conversation, not the test. ACS moves it to 40 for men with more than one first-degree relative diagnosed at an early age.
Clinicians should offer prostate cancer screening beginning at age 40 to 45 years for people at increased risk of developing prostate cancer based on the following: Black race, germline mutations, strong family history of prostate cancer.
Our note: AUA labels this a Strong Recommendation, Evidence Level Grade B. The 40 to 45 span is when screening should BEGIN, not a window that closes: AUA sets no end age here. Page dated only "Published 2023; Amended 2026"; the day is from AUA's press release of 26 February 2026.
Clinicians may begin prostate cancer screening and offer a baseline PSA test to people between ages 45 to 50 years.
Our note: AUA labels this a Conditional Recommendation, Evidence Level Grade B, meaning may, not should. The 45 to 50 span is when a baseline test may be offered, not a window that closes. Page dated only "Amended 2026"; day from AUA's 26 February 2026 press release.
Clinicians should offer regular prostate cancer screening every 2 to 4 years to people aged 50 to 69 years.
Our note: AUA labels this a Strong Recommendation, Evidence Level Grade A. It sets no fixed stop age: clinicians may personalize the interval or discontinue, on preference, age, PSA, risk, life expectancy and health. Page dated only "Amended 2026"; day from the 26 February 2026 release.
Why they differ
These three do not disagree about the trials. They disagree about how much the harms of PSA screening have changed since those trials ran, and it produces genuinely different instructions.
- USPSTF gives 55 to 69 a grade C: offer it, but only to a man who has weighed it and asked. It counts a small mortality benefit against false positives, biopsy complications, overdiagnosis in an estimated 20 to 50 percent of screen-detected cancers, and treatment harms including incontinence and erectile dysfunction. It recommends against screening at 70 and older.
- AUA, amended in 2026, makes regular screening every 2 to 4 years from 50 to 69 a Strong Recommendation on Grade A evidence, and tells clinicians to offer screening "beginning at age 40 to 45 years" to Black men and other higher-risk groups. Its pathway puts MRI and risk calculators between a raised PSA and a biopsy, and active surveillance between a diagnosis and treatment, which is how it separates finding a cancer from treating one.
- ACS recommends neither. What it recommends at 50, or 45 for Black men and men with a family history, is an informed decision with a clinician. It sets no age at which a man should simply be tested.
USPSTF itself flags the mechanism at issue. Explaining why it moved from a grade D in 2012 to a C in 2018, it cites "new evidence about and increased use of active surveillance of low-risk prostate cancer, which may reduce the risk of subsequent harms from screening." AUA has since pushed that logic further than USPSTF has. Note the dates: USPSTF's statement is from 2018 and its own page says the topic is under update, while AUA's was amended in February 2026.
One thing all three agree on and it is worth more than the disagreement: Black men develop prostate cancer earlier and die of it more often, and two of the three respond by starting the conversation five to ten years sooner.
What the test involves
PSA is an ordinary blood draw with no preparation. Two things do skew it, so time the test: avoid ejaculation and vigorous cycling for about 48 hours beforehand, and do not test within a month or two of a urinary infection, a prostate procedure or a biopsy. A digital rectal exam, if done, takes seconds and is uncomfortable rather than painful.
If the result is abnormal
A raised PSA is not a diagnosis and modern practice deliberately slows down at this point. AUA's guideline says that for a newly elevated PSA, clinicians should repeat the PSA before moving to a secondary biomarker, imaging or biopsy, and that they may use MRI before a first biopsy to improve detection of the cancers that matter. It also says that when the risk of clinically significant cancer is low enough on the available data, clinician and patient may forgo a near-term biopsy.
If a biopsy does find cancer, AUA states that clinicians should tell patients a biopsy may identify a cancer with a low enough risk of mortality that it could safely be monitored with active surveillance rather than treated. That option is the main reason a diagnosis today does not automatically mean surgery or radiation.
More on this screening
Frequently asked questions
Should I get a PSA test at 50?
Depends which body your clinician follows. AUA says yes, regular screening every 2 to 4 years from 50 to 69, and calls it a strong recommendation. USPSTF would not start until 55 and only after you have weighed it yourself. ACS recommends that you have the conversation at 50, and leaves the test to what you decide in it. None of the three says everyone should simply be tested.
I am Black. Should I start earlier?
Two of the three say yes. ACS moves the conversation to 45, naming African American men specifically. AUA says clinicians should offer screening beginning at 40 to 45 for people at increased risk, naming Black race first. USPSTF names African American men as one of the most important risk factors but sets no earlier start age for them, which is one of the clearest gaps between these documents.
Why does the USPSTF sound so lukewarm about it?
Because it weighs the harms heavily and its statement is from 2018. It counts false positives, biopsy complications, overdiagnosis of cancers that would never have caused symptoms, and treatment side effects including incontinence and erectile dysfunction. Its grade C means the decision belongs to the individual, not that screening is useless, and it explicitly credits active surveillance for improving the balance since its 2012 statement. Its own page says the topic is currently being updated.
Does a high PSA mean I need a biopsy?
Not immediately, and this has changed. AUA now says to repeat the PSA before ordering a biomarker, imaging or a biopsy, and to consider MRI first, because it improves detection of the cancers worth finding. It also says a biopsy can be deferred when the available clinical, laboratory and imaging data put the risk of significant cancer low enough. PSA rises with an enlarged prostate, inflammation, infection, recent ejaculation and cycling.
When do I stop?
USPSTF recommends against PSA screening at 70 and older. AUA sets no fixed stop and says the interval, or stopping altogether, should be personalized on preference, age, PSA, risk, life expectancy and general health. ACS publishes no stop age either, but says men with less than a 10-year life expectancy should not be offered screening.